Grape King Bio Clarifies Report Projecting NT$10 Billion Revenue in 2026
() -- Grape King Bio (TPE:1707) clarified a Commercial Times report stating the company is targeting NT$10 billion in annual revenue, noting that the figure was based solely on projections from institutional investors and not on company guidance. The biotech company said its annual revenue had already exceeded NT$10 bi